ANIKA THERAPEUTICS INC
ANIKNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $9.01 β $22.88
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 13.4M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $113M
- Last Q Revenue
- $33M
- P/E Ratio
- β
- P/S Ratio
- 2.4x
- EPS (TTM)
- $-0.27
- Dividend Yield
- β
- Dilution (1yr)
- β0.4%
ANIKA THERAPEUTICS INC
ANIKAbout ANIKA THERAPEUTICS INC
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.